178 related articles for article (PubMed ID: 37646657)
1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM; Efebera YA; Hájek R; Straub J; Maisnar V; Eveillard JR; Karlin L; Mateos MV; Oriol A; Ribrag V; Richardson PG; Norin S; Obermüller J; Bakker NA; Pour L
Haematologica; 2024 Mar; 109(3):867-876. PubMed ID: 37646657
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L; Szarejko M; Bila J; Schjesvold FH; Spicka I; Maisnar V; Jurczyszyn A; Grudeva-Popova Z; Hájek R; Usenko G; Thuresson M; Norin S; Jarefors S; Bakker NA; Richardson PG; Mateos MV
Haematologica; 2024 Mar; 109(3):895-905. PubMed ID: 37646660
[TBL] [Abstract][Full Text] [Related]
3. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
[TBL] [Abstract][Full Text] [Related]
4. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
[TBL] [Abstract][Full Text] [Related]
5. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Richardson PG; Oriol A; Larocca A; Bladé J; Cavo M; Rodriguez-Otero P; Leleu X; Nadeem O; Hiemenz JW; Hassoun H; Touzeau C; Alegre A; Paner A; Maisel C; Mazumder A; Raptis A; Moreb JS; Anderson KC; Laubach JP; Thuresson S; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Mateos MV;
J Clin Oncol; 2021 Mar; 39(7):757-767. PubMed ID: 33296242
[TBL] [Abstract][Full Text] [Related]
6. Melflufen for relapsed and refractory multiple myeloma.
Oriol A; Larocca A; Leleu X; Hajek R; Hassoun H; Rodríguez-Otero P; Paner A; Schjesvold FH; Gullbo J; Richardson PG
Expert Opin Investig Drugs; 2020 Oct; 29(10):1069-1078. PubMed ID: 32924646
[TBL] [Abstract][Full Text] [Related]
7. Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
Schjesvold FH; Ludwig H; Mateos MV; Larocca A; Abdulhaq H; Norin S; Thuresson M; Bakker NA; Richardson PG; Sonneveld P
Eur J Haematol; 2024 Mar; 112(3):402-411. PubMed ID: 37968873
[TBL] [Abstract][Full Text] [Related]
8. Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Bringhen S; Voorhees PM; Plesner T; Mellqvist UH; Reeves B; Sonneveld P; Byrne C; Nordström E; Harmenberg J; Obermüller J; Richardson PG
Br J Haematol; 2021 Jun; 193(6):1105-1109. PubMed ID: 33403663
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.
Mateos MV; Spencer A; Nooka AK; Pour L; Weisel K; Cavo M; Laubach JP; Cook G; Iida S; Benboubker L; Usmani SZ; Yoon SS; Bahlis NJ; Chiu C; Ukropec J; Schecter JM; Qin X; O'Rourke L; Dimopoulos MA
Haematologica; 2020; 105(2):468-477. PubMed ID: 31221782
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
11. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A; Chanan-Khan A; Weisel K; Nooka AK; Masszi T; Beksac M; Spicka I; Hungria V; Munder M; Mateos MV; Mark TM; Qi M; Schecter J; Amin H; Qin X; Deraedt W; Ahmadi T; Spencer A; Sonneveld P;
N Engl J Med; 2016 Aug; 375(8):754-66. PubMed ID: 27557302
[TBL] [Abstract][Full Text] [Related]
13. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
15. Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Jessee JK
Ann Pharmacother; 2022 Aug; 56(8):951-957. PubMed ID: 34963319
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.
Narsipur N; Bulla S; Yoo C; Do B; Tran K; Gu D; Zhong L; Wilson L
J Manag Care Spec Pharm; 2021 Dec; 27(12):1691-1702. PubMed ID: 34818089
[No Abstract] [Full Text] [Related]
18. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P
Lancet Haematol; 2023 Oct; 10(10):e813-e824. PubMed ID: 37793772
[TBL] [Abstract][Full Text] [Related]
20. Melflufen for the treatment of multiple myeloma.
Ocio EM; Nadeem O; Schjesvold F; Gay F; Touzeau C; Dimopoulos MA; Richardson PG; Mateos MV
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):371-382. PubMed ID: 35723075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
